Clinical trial
A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
NCT05056727 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 30, 2021
- Completion date
- February 7, 2024
- Enrollment
- 1,112 (actual)
- Sites
- 276
Conditions
As the registry lists them; a condition with its own page is linked.